miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition

Published:2013-10-29 Issue:22 Volume:105 Page:1750-1758
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Sun Chaoyang,Li Na,Yang Zongyuan,Zhou Bo,He Yang,Weng Danhui,Fang Yong,Wu Peng,Chen Pingbo,Yang Xiaokui,Ma Ding,Zhou Jianfeng,Chen Gang

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/105/22/1750/17312801/djt302.pdf

Reference43 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. The contribution of BRCA1 and BRCA2 to ovarian cancer;Ramus;Mol Oncol,2009

3. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors;David;Journal of Clinical Oncology,2002

4. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer;Yang;JAMA,2011

5. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin;Bhattacharyya;J Biol Chem,2000

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metformin combined with cisplatin reduces anticancer activity via ATM/CHK2-dependent upregulation of Rad51 pathway in ovarian cancer;Neoplasia;2024-11

2. A miRNA-7704/IL2RB/AKT feedback loop regulates tumorigenesis and chemoresistance in ovarian cancer;Experimental Cell Research;2024-04

3. Drug resistance in ovarian cancer: from mechanism to clinical trial;Molecular Cancer;2024-03-28

4. Comprehensive analysis of the miRNA-mRNA regulatory network involved in spontaneous recovery of an H2O2-induced zebrafish cataract model;Experimental Eye Research;2024-03

5. Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors;Cancer Drug Resistance;2024-02-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3